期刊文献+

罗非昔布的合成工艺优化

Optimization of Synthetic Technology of Rofecoxib
下载PDF
导出
摘要 对罗非昔布原料药的合成工艺进行优化,为以罗非昔布为原料的研究奠定基础。苯甲硫醚经傅克乙酰化得1-[4-(甲硫基)苯基]-乙酮(3),化合物3在冰醋酸中直接用双氧水氧化得1-[4-(甲磺酰基)苯基]-乙酮(4),无需纯化,直接以溴素溴化,最后与苯乙酸缩合、环合生成COX-2选择性抑制剂罗非昔布(1)。研究了影响每步反应的因素,包括溶剂的选择、反应温度与反应时间的考察、催化剂用量选择、后处理等,总收率为62%。 The synthetic technology of rofecoxib was optimized, which laid the foundation for the study withroofecoxib as raw material. 1-(4-methylsulfanyl-phenyl) -ethanone (13) was obtained by thioanisole via Friedel craftsacetylation. Then it was oxidized with hydrogen peroxide in acetic acid to obtain 1 - (4 -methanesulfonyl - phenyl) -ethanone ( 14 ) . Without purification, it was bromized with bromine. Then it was condensed and cyclized withphenylacetic acid to generate COX-2 selective inhibitor rofecoxib (1). Various reaction factors were studied, includingthe choice of solvent, reaction temperature and reaction time, catalyst dosage, treatment after reaction, and the overallyield was 62%.
作者 刘改枝 田效志 贾永艳 关延彬 张京玉 LIU Gai-zhi, TIAN Xiao-zhi, JIA Yong-yan, GUAN Yan-bin, ZHANG Jing-yu(College of Pharmacy, Henan University of Chinese Medicine, Henan Zhengzhou 450046, Chin)
出处 《广州化工》 CAS 2018年第15期45-46,60,共3页 GuangZhou Chemical Industry
基金 河南省高等学校重点科研基金(No.16A350001)
关键词 罗非昔布 COX-2抑制剂 合成工艺 rofecoxib COX-2 inhibitor synthetic technology
  • 相关文献

参考文献3

二级参考文献28

  • 1[1]Scott LJ,Lamb HM.Rofecoxib[J].Drugs,1999,58(3):499-505.
  • 2[2]Tillyer RD,Dolling UH,Frey LF,et al.Process of preparing phenyl heterocycles useful as COX-2 inhibitors[P].WO:9800416,1998-01-08.(CA 1998,128:114869)
  • 3[3]Cutler RA.New antibacterial agents 2-acylamino-1-(4-hydrocarbonylsulfonyl-phenyl)-1,3-propanediols and related compounds[J].J Am Chem Soc,1952,74:5475-5480.
  • 4[4]Gregory WA.Alpha-halogenated alkylsulfonylacetophenones[P].US:2763692,1956-09-18.(CA 1957,51:4429f).
  • 5HawkeyCJ.COX-2inhibitors[J].Lancet,1999,353∶307-314.
  • 6EhrichEW,DallobA,LepeleireID,etal.Characterizationofrofecoxibasacyclooxygenase-2isoforminhibitoranddemonstrationofanalgesiainthedentalmodel[J].ClinPharmacolTher,1999,65∶336-347.
  • 7MerckandCo.Inc.VioxxTMPrescribinginformation[R].NewJersey,USA.1998.
  • 8SaagK,FisherC,MckayJ,etal.MK-0966,aspecificCOX-2inhibitorshasclinicalefficacycomparabletoibuprofeninthetreatmentofkneeandhipOAinasix-weekcontrolledclinicaltrial[J].ArthritisRheum,1998,41(Suppl9)∶S84.
  • 9CannonG,CaldwellJ,HoltP,etal.MK-0966,aspecificCOX-2inhibitor,hasclinicalefficacycomparabletodiclofenacinthetreatmentofkneeandhipOAina26weekcontrolledclinicaltrial[J].ArthritisRheum,1998,41(Suppl9)∶S83.
  • 10MorrisonBW,DanielsSE,KoteyP,etal.Rofecoxib,aspecificcyclooxygenase-2inhibitor,inprimarydysmenorrhea:arandomizedcontrolledtrial[J].ObstetGynecol,1999,94(4)∶504-508.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部